CDX
Granta-519
Tumor indication
Lymphoma
Tumor subtype
B cell lymphoma
Description
GRANTA-519 (Mantle Cell Lymphoma CDX Model)
The GRANTA-519 cell line was derived from a patient with mantle cell lymphoma (MCL). It represents an aggressive non-Hodgkin’s lymphoma subtype with poor outcomes. GRANTA-519 is a well-established model for hematology drug research. Its biology reflects clinically relevant features of MCL progression.
Key Features:
- Derived from mantle cell lymphoma.
- B-cell non-Hodgkin’s lymphoma model.
- Aggressive growth in xenograft settings.
- Suitable for hematology research.
Applications:
GRANTA-519 is applied in studies of MCL drug discovery and biomarker development. It supports evaluation of novel agents targeting B-cell malignancies. Researchers use it to study signaling pathways and therapy resistance. Its reproducibility makes it valuable for translational lymphoma research.
Details
- Tumor indication
- Lymphoma
- Tumor subtype
- B cell lymphoma
- Organism
- Human
- Mouse sex
- Female
- Lumin data
- Proteomics, RNA-Seq, WES
Mutated genes
Select a gene to see the variants recorded for this line.
Gene expression
Show all values
| Gene | Expression |
|---|
Expression measured across the Champions panel.
Lumin data
Request this cell line
Let's build the right study, together.
Backed by deep expertise in these models, our team will work with you to design the study around your target, line of therapy, and endpoint.